A newly published peer-reviewed study has exposed an internal Israeli Ministry of Health pharmacovigilance dataset documenting 531 hospitalizations and 67 deaths within weeks of mass COVID-19 “vaccine” rollout.
Nearly half of all hospitalization reports involved myocarditis or pericarditis. Among people under 30, that figure surged to 151 of 211 (71.6%), including 48 patients under 18.
But the most important revelation was how early Israeli authorities had this information. By March 25, 2021, barely three months into the vaccine rollout, Israel had already reported to Pfizer 46 deaths, 157 hospitalizations, and 65 myocarditis/pericarditis cases. These were not retrospective estimates assembled years later; they came from an operational Ministry of Health pharmacovigilance dataset used to document serious events considered relevant enough to report directly to the manufacturer. The median reported interval from vaccination to death was just 3 days.
Israel had already alerted the CDC and European Medicines Agency to approximately 40 myocarditis cases by the end of February 2021. By March 25, the internal records contained the 46 deaths, 157 hospitalizations, and 65 myocarditis/pericarditis reports described above. Yet the study reconstructs a delay of roughly three to four months before the myocarditis signal was meaningfully communicated to clinicians and the public.
When the risk was finally acknowledged, the public messaging emphasized that myocarditis was “rare,” “mild,” and transient and that vaccination benefits outweighed the risks. That characterization was fraudulent given their internal record containing hundreds of serious hospitalizations, severe cardiac injury, and deaths.
Hellbound and Down 